Navigation Links
Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
Date:10/7/2010

SUNNYVALE, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Cepheid today announced that it will report financial results for its third quarter ended September 30, 2010, on Thursday, October 21, 2010, after the close of the market.

The company will host a management presentation at 2 p.m. Pacific Time on Thursday, October 21, 2010, to discuss the results.  To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (866) 788-0538 (domestic) or (857) 350 1676 (international), and entering participant code 51795047.  A replay will be available for seven days beginning at 4 p.m. Pacific Time.  Access numbers for this replay are (888) 286-8010 (domestic) and (617) 801-6888 (international), with passcode 72854495.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets.  The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.  The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges.  Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.  See http://www.cepheid.com for more information.CONTACTS:For Media Inquiries:For Investor Inquiries:Jared TiptonJacquie RossCepheid Corporate CommunicationsCepheid Investor RelationsTel: (408) 400 8377Tel: (408) 400 8329jared.tipton@cepheid.cominvestor.relations@cepheid.com
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
3. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
4. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
5. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
6. Cepheid Reports 2009 First Quarter Results
7. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
8. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
9. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
10. Cepheid to Webcast Upcoming Financial Presentations
11. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017 Bioptix, Inc. ... "Company"), announced that on January 14, 2017 the Board ... which the Company will terminate certain employees associated with ... Inc.  The Company commenced terminations on January 16, 2017 ... days.  The Company may pay severance benefits in certain ...
(Date:1/20/2017)... -- Ginkgo Bioworks, the organism company, announced today ... synthesis and assembly of DNA. The acquisition will ... DNA into Ginkgo,s automated organism engineering foundries, enabling ... new organism designs for application across a wide ... to significantly increase the world,s capacity to cost-effectively ...
(Date:1/19/2017)... LOUISVILLE, Ky. and HOUSTON ... Prenatal Inc. ("NX Prenatal") today announced the formation ... brings together leading clinicians and industry veterans who ... the company as it accelerates development of its ... positioned to provide medical, clinical and strategic guidance ...
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CESĀ® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
Breaking Biology News(10 mins):